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Haemophilus ducreyi is resistant to killing by normal serum antibody and complement. We discovered an H.
ducreyi outer membrane protein required for expression of serum resistance and termed it DsrA (for “ducreyi
serum resistance A”). The dsrA locus was cloned, sequenced, and mutagenized. An isogenic mutant (FX517) of
parent strain 35000 was constructed and characterized, and it was found to no longer express dsrA. FX517 was
at least 10-fold more serum susceptible than 35000. DsrA was expressed by all strains of H. ducreyi tested,
except three naturally occurring, avirulent, serum-sensitive strains. FX517 and the three naturally occurring
dsrA-nonexpressing strains were complemented in trans with a plasmid expressing dsrA. All four strains were
converted to a serum-resistant phenotype, including two that contained truncated lipooligosaccharide (LOS).
Therefore, serum resistance in H. ducreyi does not require expression of full-length LOS but does require
expression of dsrA. The dsrA locus from eight additional H. ducreyi strains was sequenced, and the deduced
amino acid sequences were more than 85% identical. The major difference between the DsrA proteins was due
to the presence of one, two, or three copies of the heptameric amino acid repeat NTHNINK. These repeats
account for the variability in apparent molecular mass of the monomeric form of DsrA (28 to 35 kDa) observed
in sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Since DsrA is present in virulent strains, is
highly conserved, and is required for serum resistance, we speculate that it may be a virulence factor and a
potential vaccine candidate.
Haemophilus ducreyi is the etiologic agent of chancroid, a
genital ulcer disease transmitted by sexual contact (reviewed in
references 2 and 50). Chancroid has gained importance re-
cently because it has been implicated as an independent risk
factor for the heterosexual transmission of human immunode-
ficiency virus (HIV) in Africa (2, 18, 25, 50, 54; F. A. Plummer,
M. A. Wainberg, P. Plourde, P. Jessamine, L. J. DaCosta, I. A.
Wamola, and A. R. Ronald, J. Infect. Dis. 161:810–811, 1990
[Letter]).
Several facets of H. ducreyi biology are interesting. H. ducreyi
is an obligate human pathogen and its growth is fastidious and
slow in vitro. It is unable to synthesize heme (3) and must
obtain heme compounds from its only known host, humans,
presumably by use of its heme or hemoglobin receptors (14, 15,
40, 45). Free heme, hemoglobin, or catalase (16, 48) can supply
the heme requirement for H. ducreyi in vitro; however, the
inability of a hemoglobin receptor mutant to initiate disease in
the human experimental model of H. ducreyi infection impli-
cates hemoglobin as the most important source of heme in vivo
(4a).
Serum resistance has been shown in numerous bacterial
systems to be critical for the survival of certain invading bac-
teria and the establishment of disease, since mutations which
result in the loss of serum resistance render several bacterial
pathogens avirulent (6, 10, 28, 33, 42). In most systems, the
serum-resistant phenotype requires the product of more than
one gene. H. ducreyi is resistant to high levels of normal human
serum (NHS) (up to 50%). Early studies of H. ducreyi serum
resistance by Odumeru et al. led to the conclusion that trun-
cation of lipooligosaccharide (LOS) in several strains (includ-
ing strains CIP A75 and CIP A77 used in this study) is asso-
ciated with avirulence and loss of serum resistance (30–32).
However, a recent study by Hiltke et al. (22) came to the
opposite conclusion. The impetus for the present study was our
observation that one of Odumeru’s serum susceptible strains
(CIP A75) (31) lacked a major outer membrane protein com-
mon to serum-resistant strains. The objective of this study was
to characterize the role of this protein, which we termed DsrA,
in the serum-resistant phenotype of H. ducreyi.
MATERIALS AND METHODS
Strains and media. The bacterial strains used in this study are listed in Table
1. It should be noted that two different strains of CIP 542 were used in this study
(Table 1); CIP 542 (CAN) (4) is avirulent, whereas CIP 542 (CDC) is virulent
(49). For routine growth, H. ducreyi was maintained on chocolate agar plates
obtained from the University of North Carolina Hospital Clinical Microbiology
Laboratory. This medium was prepared using Mueller-Hinton base as specified
by the manufacturer and contained no fetal calf serum. When 5% fetal calf
serum was required for optimal growth (strains CHIA and V-1157), gonococcal
medium base (GCB) (Difco) was used instead of Mueller-Hinton base and
prepared as specified by the manufacturer. Both chocolate agar media contained
Iso VitaleX and 1% autoclaved hemoglobin. Large-scale cultures of H. ducreyi
were grown in Fernbach flasks with 1 liter of GCB broth containing 5% fetal calf
serum, 1% IsoVitaleX, and 50 mg of heme per ml (14). For H. ducreyi, the
antibiotics used included chloramphenicol (1 mg/ml) or streptomycin (100 mg/
ml), which were incorporated into the GCB chocolate agar.
Escherichia coli was grown in Luria-Bertani broth or on Luria-Bertani agar
plates containing appropriate antibiotics. The antibiotics were used at the fol-
lowing concentrations for E. coli: ampicillin, 100 mg/ml; chloramphenicol, 30
mg/ml; kanamycin, 30 mg/ml; and streptomycin, 100 mg/ml.
Outer membrane isolation and analysis, SDS-PAGE, LOS, and immunoblot-
ting. Outer membranes were harvested as previously described (14). Protein
concentrations were determined using the bicinchoninic acid kit from Pierce
(Rockford, Ill.). Sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) and Western blotting were performed as previously described (14).
The LOS of H. ducreyi was prepared using the method of Hitchcock and Brown
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(23). SDS-PAGE and silver staining (51) or Western blotting with monoclonal
antibody (MAb) 3F11 (5) was used to analyze LOS.
N-terminal amino acid sequence determination. The N-terminal amino acid
sequence of DsrA was determined for strain 35000. Outer membranes were
subjected to preparative SDS-PAGE and Western transfer to polyvinylidene
difluoridine membranes. The blot was stained temporarily with Ponceau S pro-
tein stain to locate the DsrA protein, which in strain 35000 migrates just below
the 30-kDa standard protein. Antibodies were used in Western blots to unequiv-
ocally identify the proper band for sequencing; strips of the blot were probed
with rabbit anti-OpaF of gonococcal strain FA1090 and with MAb 5C9. Anti-
OpaF, for unknown reasons, cross-reacts with DsrA and MAb 5C9 reacts with a
previously described H. ducreyi lipoprotein (termed Hlp) with a similar molec-
ular mass (21). The corresponding 30-kDa OpaF-reactive band from the remain-
der of the Ponceau S-stained blot was sequenced.
Production of anti-DsrA antibodies. The antiserum to DsrA was produced as
follows. Outer membranes from H. ducreyi strain 35000 were electrophoresed on
large preparative SDS-PAGE gels (12% polyacrylamide), which were briefly
stained, and the corresponding 30-kDa band was excised and electroeluted using
a Centrilutor apparatus (Amicon) as specified by the manufacturer. Mice were
immunized a total of three times at 3-week intervals with 25 mg of gel-purified
protein per immunization. Freund’s complete adjuvant was used for the first
immunization, and Freund’s incomplete adjuvant was used for the remaining
immunizations. Serum was collected 2 weeks after the final immunization.
Chemicals and reagents. All chemicals and reagents, unless otherwise noted,
were from Sigma Chemical Co. (St. Louis, Mo.).
DNA manipulations. Standard recombinant DNA methods were used as de-
scribed by Sambrook et al. (38) or as specified by the manufacturer.
V-A PCR. Two degenerate oligonucleotides (no. 6 and 7 in Table 2; also see
Fig. 2) deduced from the N-terminal amino acid sequence specifically hybridized
to a 1.1-kb EcoRI genomic fragment (data not shown). Attempts to establish a
replicating plasmid containing this fragment by using size-selected DNA ligated
into several plasmid vectors were unsuccessful. Therefore, a series of three
separate vector-anchored PCR (V-A PCR) strategies were used to obtain se-
quencing templates of the dsrA structural gene, upstream flanking DNA, and
downstream flanking DNA. When possible, we established clones for these PCR
products (Table 1 and 2). The first V-A PCR (see Fig. 2, V-A PCR 1) used the
ligation between the 1.1-kb EcoRI size-selected DNA and vector pBluescript as
template and used 59 primer 6 and vector primer KS as amplimers. An approx-
imately 700-bp fragment was amplified, and a preliminary sequence was obtained
(this fragment was also cloned to establish pUNCH 1248). The N-terminal
sequence originally obtained from Edman degradation matched the deduced
amino acid sequence of the PCR product but was not homologous to known
sequences in databases. By coincidence, the C terminus ended with a phenylal-
TABLE 1. Bacterial strains and plasmids used in this study
Strain or plasmid Relevant genotype or phenotype Source, reference, or localeisolated
E. coli K-12
DH5aMCR recA gyrB Bethesda Research
Laboratories
H. ducreyi
35000 Wild type, parent Stanley Spinola Indiana
Univ.
FX516 35000 cointegrate; b-galactosidase positive; intermediate in FX517
construction; Cmr
This work
FX517 35000 dsrA Cmr This work
CIP 542 (CAN) Wild type (avirulent) William Albritton (13)
CIP A77 Wild type (avirulent) Robert Munson (31)
CIP 542 (CDC) Wild type (virulent) Stephen Morse (49)
H. ducreyi obtained from
Pat Totten
CIP A75 Wild type (avirulent) Pasteur Institute (31)
CHIA Wild type VDRL (12)
V-1157 Wild type Seattle (12)
M90-02 Wild type Bahamas
406 Wild type Mississippi
Plasmids
pCRII PCR cloning vector; Kanr Ampr Invitrogen
pUNCH 1248 dsrA PCR clone using primers 14 and 16 in pCRII vector This work
pLS88 Shuttle plasmid; Kanr Strr Sulr (11)
pUNCH 1254 dsrA subclone; EcoRI fragment of pUNCH 1248 in EcoRI of pLS88 This work
pUNCH 1255 Mutagenized dsrA; pUNCH 1254 mutagenized with CAT cassette from pNC40;
Kanr Cmr
This work
pRSM1791 Mutagenesis plasmid; b-gal1 Ampr (7)
pUNCH 1256 pUNCH 1255 (SmaI-HincII-Klenow) into the NotI site (Klenow) of pRSM1791 This work
pUNCH 1260 dsrA PCR clone, using primers 14 and 16 in pLSKS This work









6 This work TAYGARTAYGAYTAYGGIAARGG
7 This work TAYGAYTAYGGIAARGGIAARAARAC
8 This work GAAGGCGGTTTCGATATTAAAGTGCC
9 This work AAGAATGGATTTCTAAACAGGCTAC
10 This work CTGGTTTAGCCAACCAATCAGCATTG
11 This work CAATGCTGATTGGTTGGCTAAACCAG
12 This work GTAAAGCGATCAGTAATGCGTGAGCC
14 This work GACAGCATTCAGTGAATAATGGC
16 This work GCGGCCGCTTAGAATTCATACCCAACAGAACCACC
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anine (the terminal phenylalanine) encoded by the TTC of the 39 EcoRI site,
GAATTC (thus, there was no stop codon on this EcoRI fragment). This C-
terminal domain was similar to UspA2 and YadA (see Results), suggesting the
possibility of a PCR-generated artifact(s). To rule out a PCR artifact, additional
PCR was performed. The primers used included 59 primers 6, 8, and 9 and 39
primers 11 and 12. The last four primers were derived from the DNA sequence
obtained from the original anchored PCR product above (see Fig. 2) (data not
shown). We amplified identically sized products from total H. ducreyi chromo-
somal DNA template and the original V-A PCR 1 product by using 39 primers
from the region with homology to C-terminal YadA (primers 11 and 12) (data
not shown). Furthermore, Southern hybridization of H. ducreyi chromosomal
DNA probed with oligonucleotides 6, 7, 8, 9, 11, and 12 and the PCR EcoRI
product generated with oligonucleotides 8 and 12 all specifically recognized the
1.1-kb band (see Fig. 2) (data not shown). Taken together, these data demon-
strated that the N-terminal amino acid sequence obtained from the polyvinyli-
dene difluoride blot of the 30-kDa protein is found on the same gene product
that has C-terminal homology to virulence factors UspA2 and YadA and pro-
vided a motive to examine additional sequences.
To obtain the sequence upstream of the dsrA structural gene, a second V-A
PCR was used (see Fig. 2, V-A PCR 2). Again, the template for the PCR was the
ligation between the 1.1-kb EcoRI size-selected DNA and vector pBluescript but
the primers used were oligonucleotide 12 and vector primer KS. We amplified an
approximately 1,070-bp fragment that included the upstream EcoRI site (see Fig.
2).
To obtain sequence downstream of the dsrA gene, a third V-A PCR was used
(see Fig. 2, V-A PCR 3). Southern hybridization identified an approximately 4-kb
BglII fragment which hybridized with dsrA probes, and there are no BglII sites in
the sequence of the 1.1-kb EcoRI fragment. Fragments of BglII-restricted chro-
mosomal DNA (3 to 5 kb) were isolated and ligated to BamHI-digested, shrimp
alkaline phosphatase-treated pMCL210 vector. The ligation reaction products
were ethanol precipitated and amplified using primers 10 and vector primer T7
(promoter), yielding an approximately 2.5-kb PCR product. The products of all
three V-A PCRs were sequenced with appropriate primers to obtain preliminary
sequences, and the sequences confirmed one another (data not shown).
Commercially available PCR tubes (Ready to Go; Pharmacia) were used for
PCR. Analytical PCR (final volume, 25 ml) used single tubes, whereas prepara-
tive PCR combined the “beads” from four tubes into a single tube (final volume,
100 ml). The MgCl2 concentration in all PCR mixtures was 4 mM. The first two
V-A PCRs (V-A PCR 1 and V-A PCR 2) used 5 ml of ligation reaction mixture
and 25 pM each primer. The conditions for the first two V-A PCRs were as
follows: hot start, 5 min at 94°C; denaturing, 1 min at 94°C; annealing, 1 min at
50°C; extension, 1 min at 72°C. The conditions for the third V-A PCR (V-A PCR
3) were identical except that the extension time was 3 min.
DNA sequencing and analysis. DNA sequence analysis was performed at the
University of North Carolina at Chapel Hill Automated Sequencing Facility,
utilizing Taq terminator chemistry. The final sequences presented for strain
35000 in Fig. 2 and for the other H. ducreyi strains in Fig. 9 were obtained from
PCR products with primers 14 and 24, which flank the dsrA gene (see Fig. 2).
This PCR product from strain 35000 was also used to create shuttle plasmid
pUNCH 1260 (Table 1), which was used for complementation studies. Both
strands of the DNA were completely sequenced and assembled using the pro-
gram Sequencher 3.1 (Gene Codes). The preliminary sequence for the dsrA
structural gene from 35000 obtained by vector-anchored PCR was in complete
agreement with the final sequence presented (see Fig. 3). Amino acid alignments
were done with the Clustal algorithm in the program GeneJockeyII (BIOSOFT,
Cambridge, United Kingdom) and PAM 250 setting. Bestfit (GCG Computer
Group, Madison, Wis.) was used to generate similarity and identity scores, using
a gap weight of 8.
Plasmid constructions. Plasmid pUNCH 1248 was constructed by PCR. A
900-bp fragment was amplified from H. ducreyi strain 35000 using primers 14 and
16 (see Fig. 2) under the conditions described above for the first two vector-
anchored PCRs. The product was ligated to pCRII as specified by the manufac-
turer and transformed into Escherichia coli DH5a, and recombinants were iden-
tified by restriction analysis. E. coli harboring pUNCH 1248 grew poorly and
therefore was propagated only on agar plates to reduce the possibility of muta-
tion or deletion, but it gave rise to an occasional larger colony. Subclone pUNCH
1254 was constructed by isolating the EcoRI fragment of pUNCH 1248 and
ligating it into EcoRI-restricted pLS88. The dsrA gene of pUNCH 1254 was
mutagenized by insertion of a chloramphenicol acetyltransferase (CAT) gene
cassette into the open reading frame (ORF) to construct pUNCH 1255. To
perform this, the CAT cassette (a 1-kb BglII fragment from pNC40 treated with
Klenow to fill in the ends) was ligated into the NdeI site of pUNCH 1254
(previously treated with Klenow to produce blunt ends). pUNCH 1256 was
constructed by moving the insert from pUNCH 1255 (containing mutagenized
dsrA) into plasmid pRSM1791 for subsequent mutagenesis. This was done by
isolation of a SmaI-HincII fragment of pUNCH 1255, Klenow treatment, and
ligation into the NotI site of pRSM1791 previously treated with Klenow. Trans-
formation of E. coli DH5a MCR was performed and selection executed with
ampicillin and chloramphenicol, yielding pUNCH 1256.
Construction and characterization of an H. ducreyi dsrA mutant. An isogenic
mutant (FX517; Table 1) was constructed by allelic replacement of the wild-type
locus of strain 35000 with the mutation in pUNCH 1256, using a previous system
of mutagenesis described by Bozue et al. (7). In this procedure, a mutagenized
copy of the dsrA locus (containing the CAT cassette) was subcloned into a
plasmid expressing the lacZ gene (pUNCH 1256). H. ducreyi cells were electro-
porated with pUNCH 1256, and Cmr transformants were selected (19). These
transformants putatively contained the entire plasmid integrated due to a single
crossover event (as exemplified by FX516 [Table 1]). Individual transformants
were streaked onto chloramphenicol medium containing 5-bromo-4-chloro-3-
indolyl-b-D-galactoside (X-Gal) (40 mg/ml). Since the product of lacZ cleavage of
X-Gal is highly toxic to H. ducreyi, the cointegrates grow as tiny blue colonies (7).
The loss of the lacZ sequences and neighboring wild-type allele via a resolution
of the cointegrate results in only the mutant allele being retained (exemplified by
FX517 [Table 1]). These H. ducreyi mutants grew as normal-sized white colonies
on medium containing chloramphenicol and X-Gal, similar to other H. ducreyi
mutants containing CAT cassettes (references 15 and 16 and data not shown).
Southern blot and PCR analysis confirmed that an allelic replacement oc-
curred in the generation of H. ducreyi mutant FX517. Chromosomal DNA was
isolated from strains 35000, FX516, and FX517, digested with HincII, BglII, or
EcoRI and subjected to electrophoresis on agarose gels and bidirectional trans-
fer to Magnagraph (Micron Separations Inc.). The two blots were probed with
either the PCR product of oligonucleotides 14 and 16 or the BglII CAT fragment
from pUNCH 40. Digoxigenin-labeled, bound probe was detected with alkaline
phosphatase-labeled anti-digoxigenin antibody (Boehringer Mannheim) fol-
lowed by nitroblue tetrazolium and 5-bromo-4-chloro-3-indolylphosphate (NBT/
BCIP). PCR confirmation of the mutant utilized primers 14 and 16, which flank
the NdeI site (CAT cassette) used for gene disruption.
Complementation of FX517 and other dsrA mutants in trans. To rule out the
possibility that the serum susceptibility of dsrA mutant FX517 is due to a cryptic
mutation elsewhere on the chromosome or to polar downstream effects, we
complemented FX517 in the trans configuration. Briefly, we PCR amplified the
dsrA gene and surrounding locus using primers 14 and 24 (see Fig. 2), treated the
PCR product with Klenow, and restricted it with HindIII (which restricts just
downstream of dsrA [see Fig. 2]). After gel purification, the PCR product was
ligated into SmaI-HindIII-restricted pLSKS (55). The ligation was ethanol pre-
cipitated, and H. ducreyi strain FX517 was electroporated. Streptomycin-resistant
colonies were screened for production of DsrA by Western blotting and
confirmed by restriction analysis. One experimental transformant, pUNCH
1260dsrA, and one vector transformant were selected for further study. pUNCH
1260 and the vector pLSKS (negative control) were separately purified from H.
ducreyi strain FX517 and were each electroporated into the three naturally
occurring dsrA mutants [CIP A75, CIP A77, and CIP 542 (CAN) (Table 1)].
Serum susceptibility. The resistance of H. ducreyi to NHS serum was mea-
sured as previously described (8, 31) with the following modifications. An 18- to
24-h culture of H. ducreyi from chocolate agar plates was scraped into GCB broth
to an optical density at 600 nm of 0.2. A 1024 to 1025 dilution was made
(approximately 1 to 3,000 CFU/ml, depending on the strain), and aliquots were
mixed with pooled fresh NHS (fNHS) or heat-inactivated NHS (DNHS) (56°C
for 30 min) to a final concentration of 25 or 50% NHS. After incubation for 45
min at 35°C under 5% CO2, 100-ml aliquots were plated onto chocolate agar
plates and viable counts were measured after 48 h. Data are expressed as percent
survival in fNHS compared to survival in DNHS [(CFU in fHNS/CFU in
DNHS) 3 100]. Strains containing pUNCH 1260 or pLSKS were propagated and
plated on chocolate agar containing streptomycin at 100 mg/ml. Strains CHIA
and V-1157 grew poorly on Mueller-Hinton chocolate agar without fetal calf
serum and were grown on GCB chocolate agar containing 5% fetal calf serum.
Nucleotide sequence accession numbers. Relevant DNA and amino acid se-
quences have been submitted to GenBank (accession no. AF187001 through
AF187009).
RESULTS
Identification of a 30-kDa protein involved in serum resis-
tance. During the course of studies characterizing the H. du-
creyi interaction with polymorphonuclear leukocytes, a series
of Western blots was performed using various antibodies to the
Opa proteins from gonococci. Polyclonal antiserum to OpaF of
gonococcal strain FA1090 reacted with a protein that varied
between 28 and 35 kDa in a panel of strains (data not shown),
which we later designated DsrA. One strain, CIP A75, did not
react. CIP A75 was of interest because it had previously been
shown to be avirulent in a rabbit model of infection, to be
serum susceptible, to exhibit reduced adherence to HEp-2
cells, and to express a truncated LOS (31, 47).
To confirm that the previous cross-reactivity seen with the
anti-OpaF serum was due to the presence of DsrA and to
ascertain what percentage of strains expressed dsrA, a specific
antiserum to DsrA was generated using SDS-PAGE-purified
DsrA from H. ducreyi strain 35000 as the immunogen. A total
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of 29 geographically diverse laboratory and clinical isolates
were tested for the presence of DsrA by Western blotting using
the anti-DsrA serum, and 26 of 29 strains reacted, although the
apparent molecular mass of the reactive protein varied (Fig.
1A and data not shown). The proteins recognized in the DsrA
Western blots and the OpaF Western blot appeared to be the
same proteins based on their relative mobility and their pres-
ence or absence in each strain (data not shown).
Nine strains were chosen for study in more detail: three that
did not express or weakly expressed DsrA and six that strongly
expressed DsrA (Fig. 1A). The three nonreactive or weakly
reactive strains shown in Fig. 1A, CIP A75, CIP A77 (30–32),
and CIP 542 (CAN) (4), were previously reported to be avir-
ulent strains. DsrA-expressing strains (Fig. 1; Table 1) known
to be virulent include (i) the extensively studied human chal-
lenge strain 35000; (ii) CIP 542 (CDC), previously shown to
cause a human laboratory-acquired infection (49); and (iii)
V-1157, a strain virulent in the rabbit temperature-dependent
model of H. ducreyi infection (I. LeDuc, C. Elkins, and W.
Cameron, unpublished data).
Previous studies have documented that virulent H. ducreyi
strains are serum resistant (30). We performed serum suscep-
tibility studies with the nine selected H. ducreyi strains (Fig.
1B). The three strains which did not express or weakly ex-
pressed dsrA [CIP A75, CIP A77, and CIP 542 (CAN)] were
more serum susceptible (5, 7, and 0% survival with 50% NHS,
respectively) than were those that did express dsrA. Of the six
strains which expressed dsrA, five had more than 50% survivors
(range, 65 to 155%) when incubated in 50% NHS. One dsrA-
expressing strain (CHIA) had intermediate serum susceptibil-
ity (18% survival) and did not grow well on any medium tested
(data not shown). Thus, in these initial studies, there was a
correlation between the levels of dsrA expression, virulence,
and serum resistance, and this correlation provided the impe-
tus for further studies.
Molecular studies. Through a series of experiments involv-
ing Western blotting, immunoprecipitation, and finally N-ter-
minal amino acid sequencing, we determined that the DsrA
protein was not the same as the previously described 28-kDa
lipoprotein Hlp (reference 22 and data not shown). The N-
terminal amino acid sequence of the immunoreactive 30-kDa
DsrA protein of strain 35000 was found to be QQPPKFAGVS
SLYSYEYDYG KGKKTKSNEG. No significant homologies
were initially detected when this peptide sequence was
searched against GenBank, including gonococcal Opa pro-
teins.
Two degenerate oligonucleotides (oligonucleotides 6 and 7
[Table 2]) were synthesized based on the above N-terminal
sequence and found to hybridize specifically to a 1.1-kb EcoRI
chromosomal band from H. ducreyi strain 35000 (Fig. 2 and
data not shown). Attempts to clone this fragment were unsuc-
cessful. To obtain the sequence, three separate V-A PCRs (see
Materials and Methods for details) were used to amplify the
relevant locus and surrounding regions (Fig. 2). Additional
internal PCR and direct sequencing of the V-A PCR products
from these three reactions confirmed one another (Fig. 2; see
Materials and Methods). Analysis of this sequence revealed a
gene product that was similar to the UspA2 protein of Morax-
ella catarrhalis (1) and the YadA protein of Yersinia spp. (39).
Both of these proteins are implicated in determining important
virulence traits (including serum resistance).
DNA sequence and deduced amino acid sequence of the H.
ducreyi dsrA locus from strain 35000. The DNA sequence of
the dsrA locus, including 100 bp of sequence upstream of the
ATG start and 126 bp of sequence downstream of the TAA
termination codon, are presented in Fig. 3. The sequence was
obtained from PCR products amplified using primers 14 and
24, whose sequence are derived from DNA outside of the dsrA
ORF (Fig. 2). Putative promoter elements similar to 235 (TG
ATAA) and 210 (TATATT) E. coli consensus sequences were
identified beginning at nucleotide (nt) 13 (TTGACA) and nt
35 (TAGAAT), respectively, and were separated by 16 nt. A
putative ribosome-binding site (TAATGAGG) was found be-
ginning 13 nt upstream of the dsrA start codon. Beginning at nt
913 and ending at nt 946 was an inverted hairpin loop contain-
ing 13 matched nucleotides, consistent with a transcription
terminator. The gene located immediately downstream of dsrA
but in the opposite orientation was an ORF with homology to
hypothetical protein HI0107 of the genome sequence of H.
influenzae. The G1C content of the 1 kb of DNA sequence
presented was 34.5%, consistent with the AT-rich nature of
Haemophilus DNA.
The dsrA ORF predicted a protein of 28,215 Da, which,
when processed, would yield a mature protein of 26,375 Da, in
agreement with migration in SDS-PAGE for strain 35000 (Fig.
1). The unusual signal peptidase I cleavage site of TMA (AXA
is typical) was confirmed by Edman degradation of DsrA. Ed-
man degradation revealed identity in 28 of 30 amino acids
compared to the deduced amino acid sequence of DsrA. The
first two residues of the mature protein, QQ, were unusual in
their charges, but certain versions of YadA also begin with two
charged amino acids (see below) (37, 39). Consistent with its
outer membrane localization, DsrA contained a carboxyl-ter-
minal motif ending with a phenylalanine, which is found in the
majority of integral outer membrane proteins (41, 46). The
mature DsrA protein was predicted to be very basic, with a pI
of 9.1, accounting for its poor transfer during Western blotting
(data not shown).
Alignment of the DsrA protein with similar proteins is
FIG. 1. Distribution of the DsrA protein and serum resistance of selected H.
ducreyi strains. (A) Total cellular proteins from H. ducreyi strains were subjected
to SDS-PAGE and Western blotting using anti-DsrA mouse sera. Bound anti-
body was detected with alkaline phosphatase-conjugated secondary antibody and
BCIP/NBT substrate. An additional 20 geographically diverse H. ducreyi strains
also expressed a 28- to 35-kDa protein which reacted with this serum (data not
shown). The names of strains are indicated above each lane. Shown to the left of
the gel are molecular mass standards. (B) Bactericidal killing of selected H.
ducreyi strains in 50% NHS. H. ducreyi was mixed with either DNHS or fNHS for
45 min, and viable counts were determined. The percent survival in fNHS
compared to DNHS (designated 100%) is shown on the y axis. The data are
compiled from separate experiments done on at least three different days.
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shown in Fig. 4. DsrA was most similar to UspA2 and YadA in
a region of the C terminus and was most divergent in the N
terminus. The Bestfit program showed that DsrA was 45%
similar and 40% identical to UspA2 and 47% similar and 39%
identical to YadA. It should be noted that both of these het-
erologous proteins are considerably larger than DsrA, which
may account for their differences in the N-terminal domains.
The C terminus of YadA is believed to be anchored in the
outer membrane, and the N terminus is believed to contain the
functional regions of the YadA protein (34, 35, 43).
Construction and characterization of an H. ducreyi dsrA
mutant. An isogenic mutant (FX517; Table 1) was constructed
by allelic replacement of the wild-type dsrA locus of strain
35000. Initial attempts to obtain a double crossover with a
CAT cassette in the cloned dsrA gene were unsuccessful when
pUNCH 1255 was used (data not shown). Therefore, we used
a recently described two-stage method to obtain mutants (7)
(see Materials and Methods). Using this procedure, several
chloramphenicol-resistant cointegrates were obtained. After
each cointegrate was streaked onto X-Gal chocolate plates,
several mutants were obtained for each cointegrate, none of
which expressed dsrA (data not shown). One mutant, FX517,
was selected for further study. Outer membranes were pre-
pared from the parent and mutant strain FX517 and subjected
to SDS-PAGE and Coomassie staining or SDS-PAGE and
Western blotting (Fig. 5A and B, respectively). DsrA, an abun-
dant outer membrane protein in strain 35000, was absent in the
mutant. No reactivity was obtained from FX517 when anti-
DsrA antiserum (Fig. 5B) or anti-OpaF (data not shown) was
used.
DsrA, like UspA2 and YadA, had a propensity to form
complexes or putative multimers, especially when solubilized
at the lower temperature of 37°C (Fig. 1A and 5A and data not
shown). The major multimeric form migrates very near the
bovine serum albumin standard (66 kDa) and may represent a
homodimer, since electroelution and boiling of this form con-
verted it predominantly to the monomer form in SDS-PAGE
gels (data not shown). No other major H. ducreyi outer mem-
brane protein was observed after boiling the electroeluted
samples, but we cannot exclude the presence of other minor
proteins as part of this complex.
The structure of the mutagenized dsrA locus in FX517 was
confirmed by PCR and Southern blotting. PCR of the dsrA
locus in strains 35000 and FX517 with primers 9 and 12, which
flank the CAT insertion (Fig. 2), resulted in PCR products of
500 and 1,500 bp, respectively. The 1,000 bp difference in size
is presumed to be due to the CAT cassette present in FX517
(data not shown).
Chromosomal DNA from the parent and FX517 were di-
gested with HincII, BglII, or EcoRI and probed in Southern
blots using dsrA and CAT probes. Since HincII does not re-
strict dsrA or CAT, the band recognized by the dsrA probe
increased slightly in size in the mutant compared to the parent.
The exact sizes of these HincII fragments could not be deter-
mined since they were in a region of the gel that was poorly
resolved. In an identical blot, the CAT probe recognized only
the larger HincII band of the mutant (data not shown). As
predicted, the BglII and EcoRI digestions introduced novel
sites in the mutant dsrA gene, resulting in appropriately sized
hybridizing bands (data not shown). Taken together, these data
are consistent with an allelic replacement event.
Serum resistance phenotype of the dsrA mutant. The serum
susceptibility of the naturally occurring dsrA mutants and the
role of the related YadA and UspA2 proteins in mediating
serum resistance prompted us to test FX517 for serum sensi-
tivity. Studies of serum killing of parent strain 35000 and dsrA
mutant FX517 were performed using 25 and 50% pooled NHS
(Fig. 6). FX517 was highly susceptible to NHS and demon-
strated 0 and 2% survival in 50 and 25% NHS, respectively. In
contrast, parent strain 35000 was relatively serum resistant,
exhibiting 79 and 50% survival in 50 and 25% NHS (P 5 0.002
and 0.004 for 50 and 25% NHS, respectively, using Student’s
paired t test). Thus, DsrA was essential for expression of a
serum-resistant phenotype.
FIG. 2. Restriction map of the dsrA region and PCR products. The dsrA ORF is boxed. The restriction sites are indicated. The numbered arrows indicate the
direction and position of the dsrA oligonucleotides used for PCR. KS and T7 (promoter) refer to the vector primers used in the vector-anchored PCR reactions. Since
oligonucleotides 6 and 7 were deduced from the amino acid sequence of the mature, processed protein, their position was placed just slightly inside the ORF. P,
promoter. The jagged lines represent approximately 2 kb of sequence not shown downstream of the dsrA locus. The products of V-A PCR 1 and standard PCR were
used to generate plasmids pUNCH 1248 and pUNCH 1260, respectively.
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Complementation of dsrA mutants. It was possible that a
cryptic mutation (other than the dsrA mutation) had occurred
during the construction of FX517, which could account for its
serum susceptible phenotype. Furthermore, we wished to de-
termine whether the serum susceptibility of FX517 and the
three naturally occurring dsrA mutants could be converted to
serum resistance if they expressed dsrA. Each dsrA mutant
[isogenic mutant FX517 or naturally occurring mutants CIP
A75, CIP A77, and CIP 542 (CAN)] was electroporated with
pUNCH 1260 (dsrA) or pLSKS (vector control) plasmids.
These shuttle plasmids are able to replicate in H. ducreyi.
Strains containing pUNCH 1260, but not pLSKS, expressed
dsrA (Fig. 7A). Expression of dsrA from plasmid pUNCH 1260
suggested that the tentatively identified promoter (Fig. 3) was
driving expression of the cloned dsrA gene, since very little
additional upstream DNA was present and the insert was in
the opposite direction with respect to the lacZ promoter in
pLSKS.
Bactericidal assays were performed on each of the comple-
mented dsrA mutants (Fig. 7B). Expression of dsrA from
pUNCH 1260 conferred serum resistance on all four strains
[FX517, CIP A75, CIP A77, and CIP 542 (CAN)]. However,
FIG. 3. DNA sequence and deduced amino acid sequence of the dsrA locus. The putative 235 and 210 promoter sequences are indicated and underlined. A
putative ribosome-binding site is labeled RBS and underlined. A total of 21 amino acids comprising the signal peptide are underlined. The stop codon TAA is indicated
by an asterisk. The opposing arrows show a potential stem-loop transcription terminator.
FIG. 4. Comparison of the amino acid sequence of DsrA with related proteins. The amino acid sequences of the C-terminal domains of the DsrA protein of H.
ducreyi, the UspA2 protein of M. catarrahalis, and the YadA protein of Y. enterocolitica are compared. Shaded, boxed residues indicate identical or conserved residues.
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these four strains harboring the plasmid vector lacking an
insert were not resistant. We concluded that the serum suscep-
tibility defect in FX517 was due to the dsrA mutation and not
to a polar effect or cryptic mutation. Similarly, the serum sus-
ceptibility defect in the naturally occurring dsrA mutants was
repaired by a cloned dsrA.
LOS expression by H. ducreyi. In some bacterial systems,
mutants with mutations in LOS are more serum susceptible
than are wild-type strains. Indeed, the serum susceptible phe-
notype of H. ducreyi strains CIP A75 and CIP A77 was attrib-
uted to their LOS truncation. It was possible that the lack of
dsrA expression in dsrA mutants [FX517, CIP A75, CIP A77,
and CIP 542 (CAN)] resulted in the truncation of LOS directly
or indirectly. Alternatively, repair of dsrA expression in LOS
dsrA apparent double mutants (CIP A75 and CIP A77) might
affect LOS expression and subsequent serum susceptibility. To
address these possibilities, LOS were analyzed by SDS-PAGE
and silver staining (Fig. 8) and in Western blots (data not
shown). We compared 35000 and FX517 LOS (without plas-
mids) in several silver-stained gels and found that the migra-
tion patterns were similar. Furthermore, Western blots of
35000 and FX517 LOS with anti-LOS MAb 3F11 (5) were
similar (data not shown).
The silver-staining patterns of complemented dsrA mutants
were indistinguishable between each pair of strains containing
either pUNCH 1260 (dsrA) or pLSKS, respectively. There was
a minor variation in a faster-migrating LOS band for one of the
strains [CIP 542 (CAN); no plasmid present] when grown on
antibiotic-free chocolate medium (Mueller Hinton base) com-
pared to the same strain [CIP 542 (CAN), either plasmid
present] grown on streptomycin chocolate medium (gonococ-
cal medium base). However, within each pair of matched
strains (expressing or not expressing dsrA), there were no ma-
jor LOS differences. Thus, under the limited conditions exam-
ined here, the presence of DsrA and not LOS length was the
dominant determinant of serum resistance.
Structural analysis of dsrA in other H. ducreyi strains. West-
ern blotting of a variety of H. ducreyi strains (Fig. 1A) strongly
suggested that DsrA varied in molecular mass and/or amino
acid sequence(s) among the strains. Furthermore, we desired
to understand whether mutations had occurred in the naturally
occurring dsrA mutants or whether the possibility of phase
variation could account for their inability to express dsrA. PCR
was used to amplify a 1.2-kb fragment containing dsrA from
eight additional strains, including the dsrA mutants (Fig. 2,
primers 14 and 24). The deduced amino acid sequence indi-
cated that, overall, the DsrA protein was quite similar between
strains (Fig. 9). Two regions with modest variability were ob-
served and designated variable regions 1 and 2 (VR1 and
VR2). VR1 included, roughly, amino acids 90 to 100 (depend-
ing on the strain), and a few substitutions and insertions were
noted. VR2 contained either one, two, or three identical copies
of the heptamer repeat sequence NTHNINK and spanned
amino acids 174 to 195 in the various strains. It is likely that the
different number of repeat sequences was the predominant
factor accounting for the variable migration seen in SDS-
PAGE and Western blotting. Except for the DsrA protein in
mutant strain CIP 542 (CAN), which contained a stop codon
(see below), the sequences of all other eight DsrA proteins
were identical after VR2, the same region which was similar to
FIG. 5. SDS-PAGE and Western blotting of parent strain 35000 and dsrA
mutant FX517. (A) Outer membranes were prepared, solubilized at 37 or 100°C,
and subjected to SDS-PAGE and Coomassie blue staining. (B) For the Western
blot, outer membranes were solubilized at 100°C, transferred to nitrocellulose,
and probed with anti-DsrA mouse serum. Bound antibody was detected with
alkaline phosphatase-conjugated secondary antibody and BCIP/NBT substrate.
The asterisks indicate the positions of the DsrA protein. STD, molecular weight
standards.
FIG. 6. Bactericidal killing of parent strain 35000 and dsrA mutant FX517.
Bactericidal killing was performed as in Fig. 1, except that two serum concen-
trations were used. The data presented in Fig. 1 and 6 for strain 35000 with 50%
sera are the same data. The data presented for FX517 were obtained in parallel
experiments with strain 35000.
FIG. 7. Complementation of dsrA mutants and bactericidal killing. (A) Total
cellular proteins from the indicated H. ducreyi strains were subjected to SDS-
PAGE (12% polyacrylamide) and Western blotting with anti-DsrA antisera.
Bound antibody was detected with horseradish peroxidase-conjugated secondary
antibody followed by chemiluminescence. Plasmids: A, pUNCH 1260 (contains
the entire dsrA ORF from strain 35000 and its putative native promoter as
illustrated in Fig. 2); B, pLSKS (vector without insert). (B) Bactericidal killing of
the complemented dsrA mutants. Bactericidal killing was performed as in the
experiment in Fig. 1 (50% serum), except that the medium used contained
streptomycin. %, percent survival. The data are compiled from separate exper-
iments done on at least three different days.
1614 ELKINS ET AL. INFECT. IMMUN.
UspA2 and YadA. We conclude that DsrA is highly conserved
in sequence, despite its variable mobility in gels.
The stop codon present in dsrA mutant CIP 542 would result
in a truncated protein lacking the C-terminal 15 amino acids.
This region of many outer membrane proteins includes an
anchoring signal required for proper export of outer mem-
brane proteins (41, 46). This mutation might result in protein
instability and account for our inability to detect it. In contrast,
dsrA mutants CIP A75 and CIP A77 both contained an intact
ORF that would encode a full-length protein. However, exam-
ination of the promoter region of both CIP A75 and CIP A77
revealed that a 5-base deletion was present between the puta-
tive 235 and 210 regions of the promoter region (data not
shown), leaving a spacing of only 11 between the consensus
sequences. This might result in reduced or absent transcrip-
tion. In some Western blots of CIP A75 and CIP A77, a very
weak band was observed. Whether this represents weak ex-
pression of dsrA or cross-reactivity with another protein is not
known.
Examination of the DNA sequences for typical motifs in-
volved in phase variation was unrewarding. Furthermore, we
performed sequential bactericidal killing studies using 108
CFU of CIP A75 or CIP A77 to select a serum-resistant
(phase) variant expressing dsrA (data not shown). The survi-
vors from sequential fNHS treatment were just as susceptible
as the survivors from DNHS treatment, and none expressed
dsrA. These data indicate that the inability to express dsrA by
the naturally occurring dsrA mutants is probably not due to
high-frequency phase variation.
DISCUSSION
We identified and characterized a protein, DsrA, whose
expression is required for serum resistance in H. ducreyi. The
following evidence supports this conclusion. (i) The H. ducreyi
dsrA isogenic mutant FX517 is serum susceptible compared to
its parent. (ii) Three naturally occurring serum-susceptible
strains, CIP A75, CIP A77, and CIP 542 (CAN), failed to
express dsrA or expressed reduced amounts of dsrA. (iii) When
each mutant was complemented in trans with dsrA from strain
35000, each expressed abundant amounts of dsrA and became
serum resistant.
In data not presented here, introduction of the dsrA shuttle
plasmid pUNCH 1260 into E. coli resulted in modest expres-
sion of dsrA compared to H. ducreyi. It did not render E. coli
serum resistant (data not shown). It is possible that in E. coli
the DsrA protein is not assembled or exported to the outer
membrane properly or that additional H. ducreyi components,
absent in E. coli, are required for expression of serum resis-
tance. Other H. ducreyi proteins required for full expression of
serum resistance include the simultaneous expression of both
LspA proteins (53; C. Ward and E. Hansen, Fifth Int. Symp.
Haemophilus ducreyi Pathog. Chancroid) and the major outer
membrane protein (26). Further studies are needed in this
area.
Previously, Odumeru et al. concluded that truncation of
LOS was the reason for the serum susceptibility of certain
avirulent strains including CIP A75 and CIP A77 (31, 32). Our
results and those obtained just recently by others (22; R. Mun-
son, Jr., personal communication) are in direct contradiction
to those of Odumeru et al. In the present study, we found that
expression of dsrA from plasmid pUNCH 1260 conferred se-
rum resistance to LOS mutants CIP A75 and CIP A77 without
affecting their LOS composition. Furthermore, isogenic dsrA
mutant FX517 was serum susceptible and its LOS profile was
indistinguishable from that of parent strain 35000. In a recent
study by Hiltke et al. (22), serum susceptibility in strain 35000
was unaffected by mutations in LOS. In addition, Munson and
colleagues have recently identified the LOS mutation of strain
CIP A77 as galactosyltransferase (Munson, personal commu-
nication). Upon introduction of a shuttle plasmid expressing
galactosyltransferase back into CIP A77, full-length LOS was
synthesized; however, the strain remained serum susceptible.
These results suggest that truncations in LOS have little or no
effect on the serum susceptibility of H. ducreyi.
H. ducreyi requires hemoglobin to establish infection in the
human model of experimental infection, since a mutant unable
to utilize hemoglobin is unable to form pustules or to be
recovered (4a). Since chancroid ulcers bleed readily (27, 36),
hemoglobin is present to supply the heme requirement of H.
ducreyi. However, in addition to hemoglobin, blood contains
the potent bactericidal antibody-complement system capable
of lysing gram-negative bacteria. Therefore, we speculate that
H. ducreyi has evolved, or acquired through horizontal transfer,
dsrA to resist the bactericidal activity of serum during its req-
uisite hemoglobin acquisition.
In the present study, we describe a new member of a family
of proteins that is present in a variety of gram-negative bacte-
ria, since several bacterial genomes contain genetic informa-
tion to encode protein members with similar sequences. Partial
FIG. 8. Analysis of H. ducreyi LOS by SDS-PAGE. Crude LOS was prepared as described in the text and subjected to SDS-PAGE and silver staining. None, no
plasmid present; A, pUNCH 1260 (contains the entire dsrA ORF from strain 35000 and its putative native promoter as illustrated in Fig. 2); B, pLSKS (vector without
insert).
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or complete ORFs with significant homology to the conserved
C terminus of DsrA were found in the genome-sequencing
projects from Actinobacillus actinomycetemcomitans, Pasteu-
rella multocida, and H. influenzae Rd, all three of which are
members of the family Pasteurellaecea (data not shown). How-
ever, Western blotting of a variety of 13 typeable and nontype-
able H. influenzae strains failed to detect expression of DsrA,
and several frameshifts exist in the H. influenzae Rd sequence
(17), predicted to encode a DsrA-related protein (data not
shown).
Similar to uspA2 mutants, dsrA mutants are serum suscep-
tible. In M. catarrhalis, serum resistance is strongly correlated
with disease isolates rather than strains isolated from normal
carriers (24); likewise, in the present study of H. ducreyi, serum
resistance was correlated with virulent strains and dsrA expres-
sion. Furthermore, active immunization with purified UspA
proteins (9) or passive administration of a MAb which recog-
nizes the UspA proteins (20) resulted in protection in animal
studies. In the Y. enterocolitica system, passive immunization
with anti-YadA immunoglobulin G resulted in homologous but
not heterologous protection (52). It remains to be tested
whether DsrA will also serve as an effective vaccine.
FIG. 9. Comparison of the deduced amino acid sequences of dsrA from nine H. ducreyi strains. VR1 and VR2 are indicated. Shaded, boxed residues indicate
identical or conserved residues.
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DsrA is widely distributed and immunologically conserved in
H. ducreyi. The amino acid sequences of DsrA from nine
strains indicate a high degree of conservation, suggesting that
it serves an important function. The apparent differences in
molecular mass observed by SDS-PAGE and in Western blots
could be explained by different numbers of the repeated se-
quence NTHNINK in VR2 and partially by the minor variabil-
ity in VR1. The function of the repeat sequence(s) present in
VR2 is currently under investigation.
The lesions in the three naturally occurring dsrA mutants
were identified. Interestingly, CIP A75 and CIP A77 contained
identical deduced DsrA amino acid sequences, an identical
mutant LOS phenotype on silver-stained gels, and identical
dsrA nucleotide sequences, including the identical 5-bp pro-
moter region deletion. In data not presented here, CIP A75
and CIP A77 total protein profiles analyzed by SDS-PAGE on
large gels and Coomassie staining were indistinguishable and
suggest that these strains might actually be representatives of
the same isolate. We studied two strains of CIP 542, a serum-
susceptible, avirulent strain from Canada [CIP 542 (CAN)]
and a serum-resistant, virulent strain from the Centers for
Disease Control and Prevention [CIP 542 (CDC)]. CIP 542
from the American Type Culture Collection [CIP 542 (ATCC)]
is designated the type strain for H. ducreyi. We tested CIP 542
(ATCC) for DsrA in Western blots to see if it expressed a
DsrA phenotype similar to CIP 542 (CAN) or CIP 542 (CDC).
To our surprise, we found that CIP 542 (ATCC) made abun-
dant DsrA but that the DsrA from it migrated more slowly
than did the DsrA from CIP 542 (CDC) (data not shown).
Thus, we have identified three different CIP 542 strains based
on their DsrA expression phenotype. These results suggest that
these strains are different and that they should be used with
caution, and they suggest a possible reason for incongruous
results previously reported with CIP 542.
The absence or reduced synthesis of the DsrA protein in
avirulent, serum-susceptible strains suggests that it is required
for virulence. However, additional virulence studies are re-
quired with isogenic parent-mutant pairs such as 35000 and
FX517 in the appropriate animal and human models of H.
ducreyi infection. Taken together, these data strongly suggest a
FIG. 9—Continued.
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role for DsrA in the pathogenesis of chancroid and as a po-
tential virulence factor and vaccine candidate.
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